Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites-Reference-Cited by-同舟云学术

Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites

Published:2011-12-23 Issue:4 Volume:26 Page:609-614
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Greenberg A J,Vachon C M,Rajkumar S V

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2011368.pdf

Reference46 articles.

1. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma, and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749–757.

2. Katzmann J, Dispenzieri A, Kyle R, Snyder M, Plevak M, Larson D et al. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays. Mayo Clin Proc 2006; 81: 1575–1578.

3. Kyle R, Therneau T, Rajkumar S, Larson D, Plevak M, Offord J et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 354: 1362–1639.

4. Kyle R, Therneau T, Rajkumar S, Offord J, Larson D, Plevak M et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346: 564–569.

5. Vachon C, Kyle R, Therneau T, Foreman B, Larson D, Colby C et al. Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. Blood 2009; 114: 785–790.

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple myeloma incidence and mortality trends in the United States, 1999–2020;Scientific Reports;2024-06-24

2. Multiple myeloma incidence and mortality trends in the United States, 1999-2020;2024-05-06

3. “It’s not about the money, money” - Well, actually it is. Divergent views on drivers of early phase clinical trial participation among ethnically diverse potential trial participants in the United Kingdom: A Mixed Methods Study;2024-04-05

4. Molecular Pathogenesis of Multiple Myeloma;Hematology/Oncology Clinics of North America;2024-04

5. Approaches to developing de novo cancer population models to examine questions about cancer and race in bladder, gastric, and endometrial cancer and multiple myeloma: the Cancer Intervention and Surveillance Modeling Network incubator program;JNCI Monographs;2023-11-01